Christopher Gocke

Associate Professor

1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1992 2019

Filter
Letter
2018

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C., Rosner, G., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia